With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

GSK Pharmaceuticals reports a temporary production disruption due to a fire at one of its contract manufacturing facilities; ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK) has announced that a fire incident occurred at its contract manufacturing facility, resulting in temporary production disruption of ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

GSK PLC GSK shares rose 2.35% to £13.95 Friday, on what proved to be an all-around positive trading session for the stock ...

The drugmaking giant plans to pay $1.2billion upfront to acquire Efirmosfermin from Boston Pharmaceuticals, followed by ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

Aiming to expand its hepatology portfolio, UK pharma major GSK (LSE: GSK) yesterday announced that it has entered into an ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...